Organization
UTC Therapeutics
1 clinical trial
6 abstracts
Clinical trial
A First-In-Human, Single Arm, Open-label, Phase 1 Dose-Escalation Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid TumorsStatus: Recruiting, Estimated PCD: 2025-03-01
Abstract
Effect of real-time data-driven physician engagement on appropriate precision oncology testing.Org: Diaceutics, Parsippany, NJ, Utah Tech University, St. George's University of London,
Abstract
NTRK positivity and conversion to appropriate personalized treatment.Org: Diaceutics, Parsippany, NJ, Utah Tech University, St. George Hospital,
Abstract
Differential tumor gene expression profiling of obese and non-obese patients (pts) with prostatic adenocarcinoma (PC).Org: Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, UTC Therapeutics, Huntsman Cancer Institute, University of Utah,
Abstract
Impact of synchronous (sync) vs metachronous (meta) metastasis at the presentation on survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs).Org: Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, UTC Therapeutics, Hunstman Cancer Institute at the University of Utah, City of Hope Comprehensive Cancer Center,
Abstract
The role of metabolic perturbations in mediating the effects of ambient air pollution on lung cancer in the cancer prevention studies.Org: Emory University, Atlanta, GA, USA, Atlanta Cancer Care, Galderma R&D, American Cancer Society - BrightEdge, American Cancer Society,
Abstract
Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Melbourne, Australia, Australian Catholic University, Institut Gustave Roussy, University of Paris-Saclay,